Kahn, Steven E
Cooper, Mark E
Del Prato, Stefano
Clinical trials referenced in this document:
Documents that mention this clinical trial
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
https://doi.org/10.1186/s12933-023-01802-x
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
https://doi.org/10.2337/dc20-2806
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
https://doi.org/10.1016/j.clinthera.2014.10.009
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Pancreatic Safety of Sitagliptin in the TECOS Study
https://doi.org/10.2337/dc15-2780
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
https://doi.org/10.1186/s12933-019-0921-2
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (Results)
https://doi.org/10.2337/dc17-1091
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
https://doi.org/10.2337/dc17-1778
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial
https://doi.org/10.2337/dc18-0109
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes
https://doi.org/10.2215/cjn.05280517
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial
https://doi.org/10.1016/j.ahj.2016.01.011
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
https://doi.org/10.1016/j.ahj.2011.08.004
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
https://doi.org/10.1016/s0140-6736(14)62225-x
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
https://doi.org/10.1681/asn.2019121312
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease
https://doi.org/10.2215/cjn.08780621
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
https://doi.org/10.1185/03007995.2014.890925
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
https://doi.org/10.1016/j.ahj.2013.05.007
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus
https://doi.org/10.1016/j.clinthera.2016.04.037
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
https://doi.org/10.1185/03007995.2014.919907
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
https://doi.org/10.1016/j.amjcard.2012.08.030
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
https://doi.org/10.1016/s0140-6736(13)60683-2
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study (Results)
https://doi.org/10.2337/dc20-1889
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
https://doi.org/10.1016/j.ahj.2011.08.006
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
https://doi.org/10.2337/dc14-2868
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
https://doi.org/10.2337/dc17-1736
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
https://doi.org/10.1016/j.clinthera.2011.06.016
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
https://doi.org/10.2337/dc18-1355
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
https://doi.org/10.1681/asn.2018010103
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (Results)
https://doi.org/10.2337/dc17-1096
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial (Results)
https://doi.org/10.2337/dc20-1096
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories (Results)
https://doi.org/10.2215/cjn.14901219
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
https://doi.org/10.1016/j.amjcard.2012.08.030
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
https://doi.org/10.1186/s12933-024-02328-6
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
https://doi.org/10.2337/dc18-1959
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
https://doi.org/10.1016/s0140-6736(12)61267-7
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
https://doi.org/10.2337/dc19-1065
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol
https://doi.org/10.1136/bmjopen-2014-005942
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
https://doi.org/10.2337/dc18-1871
Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL (Results)
https://doi.org/10.2337/dc19-1079
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
https://doi.org/10.1186/s12933-019-0942-x
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
https://doi.org/10.1016/j.clinthera.2014.11.008
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
https://doi.org/10.2337/dc18-2028
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (Results)
https://doi.org/10.2337/dc19-0950
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
https://doi.org/10.1186/s12933-022-01555-z
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
https://doi.org/10.2337/ds16-0026
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event
https://doi.org/10.2337/db20-1421-p
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial
https://doi.org/10.1186/s12933-020-01150-0
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
https://doi.org/10.2337/ds17-0014
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
https://doi.org/10.2337/dc18-1094
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial (Results)
https://doi.org/10.2337/dc17-1825
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
https://doi.org/10.1016/s0140-6736(12)61267-7
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial (Results)
https://doi.org/10.2337/dc20-0437
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
https://doi.org/10.2337/dc17-2677
Liraglutide Effects in Insulin-Treated Patients in LEADER
https://doi.org/10.2337/db18-438-p
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
https://doi.org/10.1016/j.ahj.2013.07.012
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial (Results)
https://doi.org/10.2337/dc17-1956
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (Results)
https://doi.org/10.2337/dc20-1622
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
https://doi.org/10.2337/dc16-2747
Liraglutide and Glycaemic Outcomes in the LEADER Trial
https://doi.org/10.1007/s13300-018-0524-z
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial (Results)
https://doi.org/10.2337/dc19-0415
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
https://doi.org/10.1016/j.clinthera.2014.11.008
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 (Results)
https://doi.org/10.2337/dci19-0067
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
https://doi.org/10.2215/cjn.11881019
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (Results)
https://doi.org/10.2337/dc19-2251
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials
https://doi.org/10.1016/j.clinthera.2014.07.020
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
https://doi.org/10.1016/j.clinthera.2014.06.008
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
https://doi.org/10.2337/dc14-2868
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
https://doi.org/10.1080/14740338.2019.1626823
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
https://doi.org/10.2337/dc18-0588
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
https://doi.org/10.2337/dc16-1371
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
https://doi.org/10.1136/bmjdrc-2014-000020
HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy
https://doi.org/10.2337/dc18-0914
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
https://doi.org/10.2337/dc17-0068
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial (Results)
https://doi.org/10.2337/dc20-0902
Documents that mention this clinical trial
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes
https://doi.org/10.1186/s12933-022-01594-6
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
https://doi.org/10.1186/s12933-021-01386-4
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
https://doi.org/10.1186/s12933-020-01179-1
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
https://doi.org/10.2337/ds16-0026
Nonglycemic Outcomes of Antidiabetic Medications
https://doi.org/10.2337/cd18-0015
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes
https://doi.org/10.1136/dtb.2020.000051
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study (Results)
https://doi.org/10.2337/dc19-1476
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
https://doi.org/10.1080/13696998.2018.1562817
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
https://doi.org/10.1161/circulationaha.119.044775
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus
https://doi.org/10.1016/j.clinthera.2016.04.037
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
https://doi.org/10.1161/circulationaha.121.058103
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Nonglycemic Outcomes of Antidiabetic Medications
https://doi.org/10.2337/cd18-0015
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 (Results)
https://doi.org/10.2337/dc20-2492
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
https://doi.org/10.2337/dc21-0076
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test (Results)
https://doi.org/10.2337/dc18-0243
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp (Results)
https://doi.org/10.2337/dc18-0244
Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study
https://doi.org/10.2337/dc21-0461
OGTT Glucose Response Curves, Insulin Sensitivity, and β-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β-Cell Function (Results)
https://doi.org/10.2337/dc20-2134
Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study
https://doi.org/10.2337/dc21-0460
Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes (Results)
https://doi.org/10.2337/dc18-1662
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test (Results)
https://doi.org/10.2337/dc18-0243
Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
https://doi.org/10.2337/dc21-0027
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp (Results)
https://doi.org/10.2337/dc18-0244
Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study
https://doi.org/10.2337/dc21-0461
OGTT Glucose Response Curves, Insulin Sensitivity, and β-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β-Cell Function (Results)
https://doi.org/10.2337/dc20-2134
Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study
https://doi.org/10.2337/dc21-0460
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes (Results)
https://doi.org/10.2337/dc19-0556
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test (Results)
https://doi.org/10.2337/dc18-0243
Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes (Results)
https://doi.org/10.2337/dc18-0787
Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
https://doi.org/10.2337/dc21-0027
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp (Results)
https://doi.org/10.2337/dc18-0244
Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study
https://doi.org/10.2337/dc21-0461
OGTT Glucose Response Curves, Insulin Sensitivity, and β-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β-Cell Function (Results)
https://doi.org/10.2337/dc20-2134
Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study
https://doi.org/10.2337/dc21-0460
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Funding for this research was provided by:
Ministero dell’Istruzione, dell’Università e della Ricerca
National Institutes of Health (DK-017047)
U.S. Department of Veterans Affairs
National Health and Medical Research Council (2010YK7Z5K_006)
This article is maintained by: Elsevier
Article Title: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Journal Title: The Lancet
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(13)62154-6
CrossRef DOI link to the associated document: https://doi.org/10.1016/S2213-8587(13)70187-6
Content Type: article
Copyright: Copyright © 2014 Elsevier Ltd. All rights reserved.